PDCD1LG2 and endometrial cancer: MSI-H/dMMR endometrial cancers are often associated with an increased number of neoantigens, PD-1 expression on tumor-infiltrating lymphocytes, and PD-L1 and PD-L2 expression on immune cells which can downregulate the patient’s immune response via PD-1 signaling [37].